NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

BDTX

Black Diamond Therapeutics Inc

Jun 23 • 04:00PM ET

2.27

Dollar change -0.06
Percentage change -2.58	%

Healthcare • Biotechnology • USA • NASD

Peers: BPMC FATE IGMS ALLO ADAP TVRD XFOR CRBP

| Held by: VTI IWM VXF FESM IWO VTWO IWN DFAT IWC DFAC

Scroll to Statements

Index	RUT	P/E	36.79	EPS (ttm)	0.06	Insider Own	23.86%	Shs Outstand	56.68M	Perf Week	-1.73%
Market Cap	129.08M	Forward P/E	-	EPS next Y	-1.02	Insider Trans	-29.89%	Shs Float	43.30M	Perf Month	11.82%
Enterprise Value	-1.73M	PEG	15.79	EPS next Q	-0.27	Inst Own	62.07%	Short Float	17.48%	Perf Quarter	27.53%
Income	5.09M	P/S	1.84	EPS this Y	88.39%	Inst Trans	-18.34%	Short Ratio	5.77	Perf Half Y	-9.20%
Sales	70.00M	P/B	0.91	EPS next Y	-589.27%	ROA	3.19%	Short Interest	7.57M	Perf YTD	6.07%
Book/sh	2.50	P/C	0.85	EPS next 5Y	2.33%	ROE	4.14%	52W High	6.75 -66.37%	Perf Year	-57.33%
Cash/sh	2.68	P/FCF	-	EPS past 3/5Y	28.55% -5.22%	ROIC	3.19%	52W Low	1.20 89.96%	Perf 3Y	7.58%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	99.51%	Volatility	1.75% 4.37%	Perf 5Y	-93.95%
Dividend TTM	-	EV/Sales	-0.02	EPS Y/Y TTM	104.65%	Oper. Margin	-5.72%	ATR (14)	0.16	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.24	Sales Y/Y TTM	-	Profit Margin	7.27%	RSI (14)	52.40	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	9.24	EPS Q/Q	378.68%	SMA20	-2.72%	Beta	2.71	Target Price	10.67
Payout	-	Debt/Eq	0.15	Sales Q/Q	-	SMA50	16.84%	Rel Volume	0.65	Prev Close	2.33
Employees	24	LT Debt/Eq	0.13	Earnings	May 12 AMC	SMA200	-11.60%	Avg Volume	1.31M	Price	2.27
IPO	Jan 30, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	4479.44% 100.00%	Trades		Volume	913,353	Change	-2.58%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-31-24	Initiated	Raymond James	Outperform	$20
Jul-14-23	Initiated	Piper Sandler	Overweight
Jun-30-23	Upgrade	Stifel	Hold → Buy	$2 → $10
Jun-28-23	Upgrade	H.C. Wainwright	Neutral → Buy	$11
Jun-27-23	Upgrade	Wedbush	Neutral → Outperform	$10
Mar-29-22	Downgrade	Wedbush	Outperform → Neutral
Mar-22-22	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-30-21	Initiated	Stifel	Hold	$10
Jan-07-21	Initiated	Wedbush	Outperform	$45
Nov-24-20	Initiated	Berenberg	Buy	$58
May-04-20	Initiated	H.C. Wainwright	Buy	$53
Feb-24-20	Initiated	JP Morgan	Overweight	$42
Feb-24-20	Initiated	Jefferies	Buy
Feb-24-20	Initiated	Cowen	Outperform
Feb-24-20	Initiated	Canaccord Genuity	Buy	$50

Show Previous Ratings

May-29-25 08:00AM	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire) +13.07%
May-12-25 04:05PM	Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +6.71% +10.29%
Apr-26-25 11:00AM	Microsoft, Apple Set To Report Earnings As Markets Watch Out For Core PCE Price Index (Seeking Alpha)
Mar-31-25 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-25-25 12:58AM	Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier (SeekingAlpha)
10:42AM	Loading…
Mar-20-25 10:42AM	Servier and Black Diamond sign deal for solid tumours therapy (Pharmaceutical Technology) +9.30%
Mar-19-25 07:00AM	Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy (GlobeNewswire)
Mar-06-25 04:09PM	Black Diamond: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-19-25 09:15AM	NAYA Biosciences Announces Nomination of New Board Members (GlobeNewswire)
Jan-12-25 06:05AM	Raymond James Predicts Up to ~930% Rally for These 2 Strong Buy Stocks (TipRanks)
Nov-05-24 09:00AM	Black Diamond: Q3 Earnings Snapshot (Associated Press Finance) +8.70%
08:00AM	Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-24 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.47%
Oct-07-24 04:01PM	Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway (GlobeNewswire)
11:43AM	Loading…
Sep-23-24 11:43AM	Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug (Benzinga) -5.46%
07:00AM	Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations (GlobeNewswire)
Sep-22-24 10:00AM	Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC (GlobeNewswire)
Sep-14-24 03:30AM	Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Aug-08-24 04:05PM	Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors (GlobeNewswire) +6.25%
12:00PM	All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy (Zacks)
Aug-06-24 01:53PM	BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q2 2024 (InvestorPlace) -5.57%
07:37AM	Black Diamond: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-29-24 08:28PM	Is Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock to Buy Right Now? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-01-24 10:00AM	Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-29-24 08:00AM	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 08:23AM	HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating (MT Newswires)
May-10-24 08:46AM	Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings? (Zacks) -9.48%
01:54PM	Loading…
May-09-24 01:54PM	BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:28AM	Black Diamond: Q1 Earnings Snapshot (Associated Press Finance)
Apr-29-24 08:50AM	Black Diamond (BDTX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Apr-25-24 09:55AM	Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect? (Zacks)
Apr-24-24 04:05PM	Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-23-24 07:45AM	Garry Menzel joins GHO Capital as Operating Partner (GlobeNewswire)
Apr-15-24 12:00PM	Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Apr-11-24 08:00AM	Black Diamond Therapeutics Announces Changes to Board of Directors (GlobeNewswire) +11.85%
Apr-08-24 09:55AM	Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know (Zacks) +5.73%
Apr-07-24 06:00PM	Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting (GlobeNewswire)
Apr-03-24 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.71%
Mar-22-24 09:55AM	How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93% (Zacks) +6.10%
Mar-14-24 05:31AM	Black Diamond Therapeutics Inc (BDTX) Reports Q4 and Full Year 2023 Financials, Advances ... (GuruFocus.com) +8.35%
Mar-12-24 08:32AM	Black Diamond: Q4 Earnings Snapshot (Associated Press Finance) -5.50%
08:00AM	Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 04:30PM	Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024 (GlobeNewswire)
Feb-28-24 08:00AM	Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-04-24 08:00AM	Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones (GlobeNewswire)
Dec-13-23 07:00AM	Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM (GlobeNewswire) -9.03%
Nov-07-23 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-06-23 08:07AM	Black Diamond Therapeutics Inc (BDTX) Reports Q3 2023 Financial Results and Corporate Update (GuruFocus.com)
07:48AM	Black Diamond: Q3 Earnings Snapshot (Associated Press Finance)
07:45AM	Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-20-23 12:54PM	Hedge Fund and Insider Trading News: John Paulson, Sanjay Shah, Doug Kass, Point72 Asset Management, Balyasny Asset Management, Black Diamond Therapeutics, Inc. (BDTX), Delta Air Lines, Inc. (DAL), and More (Insider Monkey)
Oct-14-23 12:30PM	Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535 (GlobeNewswire)
Oct-04-23 12:14PM	Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) -5.56%
Sep-18-23 12:34PM	Co-founder of cancer biotech Black Diamond replaced as CEO (American City Business Journals)
07:00AM	Black Diamond Therapeutics Announces CEO Transition (GlobeNewswire)
Sep-11-23 08:00AM	Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer (GlobeNewswire)
Sep-05-23 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-17-23 09:56AM	10 Healthcare Stocks with Insider Buying (Insider Monkey)
Aug-11-23 07:35AM	Black Diamond: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-25-23 07:43AM	Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth? (Simply Wall St.)
Jul-16-23 10:05AM	TipRanks Perfect 10 List: These Monster Growth Stocks Could Reach New Highs (TipRanks)
Jun-29-23 08:57PM	Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -12.22%
05:48PM	Why Shares of Black Diamond Therapeutics Skyrocketed This Week (Motley Fool)
Jun-28-23 04:23PM	Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) -7.28%
07:15AM	Institutions profited after Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) market cap rose US$152m last week but private equity firms profited the most (Simply Wall St.)
Jun-27-23 07:00AM	Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families (GlobeNewswire) +235.87%
Jun-13-23 08:00AM	Black Diamond Therapeutics Announces Promotion of Melanie Morrison to Chief Development Officer (GlobeNewswire) +5.34%
Jun-02-23 08:00AM	Black Diamond Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) +8.84%
May-18-23 10:17AM	Black Diamond Therapeutics Insider Ups Holding By 82% During Year \ (Simply Wall St.) -6.36%
May-09-23 07:46AM	Black Diamond: Q1 Earnings Snapshot (AP Finance) -5.21%
07:30AM	Black Diamond Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-18-23 08:00AM	Black Diamond Therapeutics to Present at the Stifel 2023 Targeted Oncology Days (GlobeNewswire)
Apr-17-23 04:01PM	Black Diamond Therapeutics Presents Trial in Progress Poster for BDTX-1535 and Preclinical Data on BDTX-1535 and BDTX-4933 at the 2023 American Association of Cancer Research Annual Meeting (GlobeNewswire)
Mar-09-23 07:52AM	Black Diamond: Q4 Earnings Snapshot (AP Finance) -13.69%
07:30AM	Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-27-23 08:00AM	Black Diamond Therapeutics to Present at the Cowen 43rd Annual Health Care Conference (GlobeNewswire) -9.31%
Feb-15-23 05:46AM	Is Black Diamond Therapeutics (NASDAQ:BDTX) In A Good Position To Invest In Growth? (Simply Wall St.) -7.72%
Jan-19-23 05:41AM	private equity firms who own 40% along with institutions invested in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) saw increase in their holdings value last week (Simply Wall St.)
Jan-05-23 08:00AM	Black Diamond Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-19-22 08:00AM	Black Diamond Therapeutics Announces Changes to Board of Directors (GlobeNewswire)
Dec-12-22 08:00AM	Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company (GlobeNewswire)
Dec-09-22 09:35AM	Down 32.6% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX) (Zacks)
09:04AM	Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) recent US$17m market cap decline means a loss of US$21k for insiders who bought this year (Simply Wall St.)
Nov-09-22 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.70%
Nov-08-22 08:00AM	Black Diamond Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-26-22 08:00AM	Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535 and BDTX-4933 at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Sep-06-22 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.51%
Aug-28-22 09:41AM	We Think Black Diamond Therapeutics (NASDAQ:BDTX) Needs To Drive Business Growth Carefully (Simply Wall St.)
Aug-09-22 08:00AM	Black Diamond Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-03-22 08:00AM	Black Diamond Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire)
Aug-01-22 08:55AM	Could The Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Jul-02-22 08:29AM	CFO, Principal Financial Officer and Chief Business Officer Fang Ni Just Bought 57% More Shares In Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) (Simply Wall St.)
Jun-06-22 08:00AM	Black Diamond Therapeutics to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
Jun-01-22 07:00AM	Black Diamond Therapeutics Appoints Sergey Yurasov, M.D., Ph.D., as Chief Medical Officer (GlobeNewswire)
May-17-22 07:00AM	Black Diamond Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +5.91%

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company's MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIOTECH GROWTH N V	10% Owner	Mar 19 '25	Sale	2.07	5,784,292	11,997,749	2,733,547	Mar 20 09:01 PM
Versant Venture Capital VI, L.	10% Owner	Aug 28 '24	Sale	6.32	221,600	1,400,556	3,726,341	Aug 30 04:16 PM
David Epstein	Former Employer	Jul 31 '24	Proposed Sale	6.20	50,000	310,000		Jul 31 04:18 PM
David Epstein	Former Employee	Jul 26 '24	Proposed Sale	6.20	50,000	310,000		Jul 26 05:54 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BDTX

Black Diamond Therapeutics Inc

Upgrade your FINVIZ experience